CJJD:NSD-China Jo-Jo Drugstores Inc (USD)

COMMON STOCK | Pharmaceutical Retailers |

Last Closing

USD 1.699

Change

+0.09 (+5.63)%

Market Cap

USD 0.01B

Volume

2.21K

Analyst Target

USD 7.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

China Jo-Jo Drugstores, Inc. operates as a retailer and wholesale distributor of pharmaceutical and other healthcare products in the People's Republic of China. The company operates through three segments: Retail Drugstores, Online Pharmacy, and Drug Wholesale. Its stores provide various pharmaceutical products, including prescription and over-the-counter drugs, nutritional supplements, traditional Chinese medicines (TCM), personal and family care products, and medical devices, as well as convenience products, such as consumable, seasonal, and promotional items. The company offers consultation, examination, and treatment of common ailments by licensed doctors in western medicine and TCM at scheduled hours. In addition, it provides treatment for minor ailments, such as sprains, minor lacerations, and dizziness; acupuncture, therapeutic massage, and cupping services; and minor outpatient surgical treatments, including suturing. Further, it offers OTC drugs and nutritional supplements through its website www.dada360.com, as well as sells products through third-party platforms. Additionally, the company distributes third-party pharmaceutical products to trading companies, as well as cultivates and wholesales herbs used for TCM. It operates pharmacies under the Jiuzhou Grand Pharmacy name. China Jo-Jo Drugstores, Inc. is headquartered in Hangzhou, the People's Republic of China.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-26 )

Largest Industry Peers for Pharmaceutical Retailers

Symbol Name Price(Change) Market Cap
WBA Walgreens Boots Alliance Inc

+0.27 (+3.27%)

USD 7.52B
HITI High Tide Inc

-0.05 (-2.50%)

USD 0.17B
PETS PetMed Express Inc

+0.09 (+2.54%)

USD 0.07B
MEDS Trxade Group Inc

-0.42 (-5.61%)

USD 0.01B
LFLYW Leafly Holdings Inc

N/A

N/A
MDVLQ MedAvail Holdings Inc

N/A

N/A

ETFs Containing CJJD

N/A

Market Performance

  Market Performance vs. Industry/Classification (Pharmaceutical Retailers) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -61.39% 33% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -61.39% 33% F 12% F
Trailing 12 Months  
Capital Gain -62.77% 33% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -62.77% 33% F 13% F
Trailing 5 Years  
Capital Gain -99.42% 33% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -99.42% 33% F 2% F
Average Annual (5 Year Horizon)  
Capital Gain -27.83% 33% F 12% F
Dividend Return -27.83% 33% F 12% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 466.59% 17% F 5% F
Risk Adjusted Return -5.96% 100% F 35% F
Market Capitalization 0.01B 20% F 12% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector